CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study

Published: 13/08/2019
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study
Source: WWW.PRNEWSWIRE.COM

SUZHOU, China, Aug. 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announces the dosing of the first patient in China for the Phase I registrational study of BLU-667, which was discovered by the company's partner Blueprint Medicines. This clinical trial is a...

Read more
Related news
Comment
FACEBOOK